KEMYTH BIOTECH
KeMyth Biotech (founded July 2015) develops research-derived tools and services focused on infectious disease and broader health applications. Core activities include a genetically engineered bacterial strain library and an antibiotic testing and screening platform, rapid lateral-flow diagnostics for Klebsiella pneumoniae capsular serotypes, preclinical pharmacokinetics/biodistribution testing, antimicrobial activity testing, custom resistant-strain construction, and development of natural-product-based beauty and health formulations. The company reports regulatory approval for its K1/K2 serotype test and holds patents for its antibiotic testing platform.
Industries
Nr. of Employees
small (1-50)
KEMYTH BIOTECH
Patents
Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
US-10287328-B2
View Details
Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
US-10287328-B2
View DetailsProducts
Klebsiella pneumoniae K1/K2 capsular serotype immunochromatographic test
Colloidal‑gold lateral‑flow cassette for rapid identification of K. pneumoniae K1 and K2 capsular serotypes for use on clinical specimens; reported clinical use in Taiwanese medical centers and TFDA marketing authorization.
Engineered Gram‑negative strain panels (research strains)
Catalog of genetically engineered K. pneumoniae, A. baumannii and P. aeruginosa strains with annotated resistance mechanisms for research and screening; associated with peer‑reviewed publications.
Natural‑product beauty and health formulations
Range of botanical extracts and consumer formulations produced using ultrasonic extraction and freeze‑drying, including powders, drinks, capsules and facial masks.
K. pneumoniae
Genetically engineered Klebsiella pneumoniae mutant library and resistance system utilized by discovery research teams to screen antimicrobial compounds and study drug permeability, uptake, and efflux mechanisms.
K. pneumoniae NVT1001 and its derived strains
克雷伯氏肺炎桿菌及其衍生基因工程工具菌株，已發表於國際學術期刊（2017, J Antimicrob Chemother）。
抗生素測試及篩選平台
An advanced system platform utilizing genetic engineering to establish resistant bacterial strains specifically for Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, enabling precise evaluation of candidate compounds against specific resistance mechanisms.
Klebsiella pneumoniae K1/K2 capsular serotype immunochromatographic test
Colloidal‑gold lateral‑flow cassette for rapid identification of K. pneumoniae K1 and K2 capsular serotypes for use on clinical specimens; reported clinical use in Taiwanese medical centers and TFDA marketing authorization.
Engineered Gram‑negative strain panels (research strains)
Catalog of genetically engineered K. pneumoniae, A. baumannii and P. aeruginosa strains with annotated resistance mechanisms for research and screening; associated with peer‑reviewed publications.
Natural‑product beauty and health formulations
Range of botanical extracts and consumer formulations produced using ultrasonic extraction and freeze‑drying, including powders, drinks, capsules and facial masks.
K. pneumoniae
Genetically engineered Klebsiella pneumoniae mutant library and resistance system utilized by discovery research teams to screen antimicrobial compounds and study drug permeability, uptake, and efflux mechanisms.
K. pneumoniae NVT1001 and its derived strains
克雷伯氏肺炎桿菌及其衍生基因工程工具菌株，已發表於國際學術期刊（2017, J Antimicrob Chemother）。
抗生素測試及篩選平台
An advanced system platform utilizing genetic engineering to establish resistant bacterial strains specifically for Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, enabling precise evaluation of candidate compounds against specific resistance mechanisms.
Services
Screening of candidate compounds against a panel of engineered Gram‑negative strains with defined resistance mechanisms.
In vitro potency testing and susceptibility profiling using the company's panels and standard methods.
Design and generation of bespoke genetically modified bacterial strains to represent specific resistance mechanisms for research and screening.
Customized animal pharmacokinetic and biodistribution studies using LC‑MS/MS, ELISA, radiotracing and imaging; support for early drug development and IND packages.
Screening of candidate compounds against a panel of engineered Gram‑negative strains with defined resistance mechanisms.
In vitro potency testing and susceptibility profiling using the company's panels and standard methods.
Design and generation of bespoke genetically modified bacterial strains to represent specific resistance mechanisms for research and screening.
Customized animal pharmacokinetic and biodistribution studies using LC‑MS/MS, ELISA, radiotracing and imaging; support for early drug development and IND packages.
Expertise Areas
- Antibiotic screening and susceptibility testing
- Genetic engineering of bacterial strains
- Preclinical pharmacokinetics and biodistribution
- Diagnostic lateral‑flow assay development
Key Technologies
- Genetic engineering of bacterial strains
- Engineered bacterial strain libraries for AMR research
- Lateral‑flow immunochromatographic assays
- Liquid chromatography–tandem mass spectrometry (LC‑MS/MS)
News & Updates
Marketing authorization issued by Taiwan Food and Drug Administration for the K. pneumoniae K1/K2 serotype antigen detection test (medical device license number 衛部醫器製壹字第010180號).
U.S. patent granted for the company's antibiotic testing and screening system (reported 2020).
Taiwan patent (Invention No. I778025) awarded for the antibiotic testing and screening platform.
Recognition: rapid identification technology for Klebsiella pneumoniae capsular serotypes received the 13th Taiwan National Innovation Award.
Marketing authorization issued by Taiwan Food and Drug Administration for the K. pneumoniae K1/K2 serotype antigen detection test (medical device license number 衛部醫器製壹字第010180號).
U.S. patent granted for the company's antibiotic testing and screening system (reported 2020).
Taiwan patent (Invention No. I778025) awarded for the antibiotic testing and screening platform.
Recognition: rapid identification technology for Klebsiella pneumoniae capsular serotypes received the 13th Taiwan National Innovation Award.